Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CANCELLATION OF THE REPURCHASED H SHARES

References are made to the circular (the "Circular") dated 7 December 2020 and the announcements dated 1 December 2020, 4 January 2021, 5 January 2021, 6 January 2021, 7 January 2021, 8 January 2021, 11 January 2021, 27 January 2021, 28 January 2021, 29 January 2021, 1 February 2021, 2 February 2021, 3 February 2021, 4 February 2021, 5 February 2021, 1 March 2021 and 1 April 2021 of 麗珠醫藥集團股份 有限公司Livzon Pharmaceutical Group Inc.* (the "Company", together with its subsidiaries, the "Group") in relation to the grant of general mandate to the Board to repurchase H shares of the Company (the "H Share Repurchase Mandate"), the monthly returns and the next day disclosure returns. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

As at 6 May 2021, the Company made a total repurchase of 6,628,600 H Shares (the "Repurchased H Shares") of the Company, accounting for 0.71% of the total issued share capital (939,881,138 shares) and 2.07% of the total number of issued H Shares (319,864,217 shares) of the Company on 6 May 2021. The highest purchase price was HK$31.90 per share and the lowest purchase price was HK$28.35 per share. The total amount of funds used was HK$199,632,345.00 (excluding transaction costs). The share repurchase mentioned above complies with the H Share Repurchase Mandate.

On 7 May 2021, the Repurchased H Shares were cancelled and the registered capital of the Company will be reduced by RMB6,628,600. The Company will go through relevant registration formalities of the change as soon as possible.

By order of the Board

麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc. *

Yang Liang

Company Secretary

Zhuhai, China

7 May 2021

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Zheng Zhihua, Mr. Xie Yun, Mr. Tian Qiusheng and Mr. Wong Kam Wa.

* For identification purpose only

1

Attachments

  • Original document
  • Permalink

Disclaimer

Livzon Pharmaceutical Group Inc. published this content on 07 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 May 2021 07:06:43 UTC.